期刊文献+

DRGs在医院绩效管理中的应用 被引量:13

Application of DRGs in Hospital Performance Management
下载PDF
导出
摘要 目的探索DRGs在医院医疗质量管理中的作用,为医院管理提供实证参考。方法选取北京市某大型三甲医院,将DRGs组数、CMI、时间消耗指数、费用消耗指数4个DRGs相关指标纳入科室绩效考核,对医院近3年的统计数据进行分析描述。结果医院疾病种类、疑难疾病占比增长明显,病案首页正确率明显提升。结论将DRGs纳入医院绩效管理有助于促进医疗质量的提升与学科建设,但应持续关注病案首页质量,对罕见病应根据医院实际情况来调整。 Objective To explore the effect of diagnosis-related groups(DRGs)in hospital medical quality management and provide an empirical reference for hospital management.Methods The DRGs,Case Mix Index(CMI),time consumption index and cost consumption index were included into the performance assessment of departments,and the statistical data of the hospital in the past three years were analyzed.Results The diseases category and proportion of difficult diseases in the hospital had increased significantly,the correct rate of the home page of medical records had obviously increased.Conclusion Incorporating DRGs into hospital performance management can promote the improvement of medical quality and discipline construction.but the quality of the home page of medical records should be continuously paid attention to,and the standard of the performance assessment of rare diseases should be adjusted appropriately according to the actual situation of the hospital.
作者 陈倩 秦明伟 周炯 范靖 黄鹂 陈政 李春厚 CHEN Qian;QIN Mingwei;ZHOU Jiong(Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing,100730,China)
出处 《中国卫生质量管理》 2019年第2期40-42,共3页 Chinese Health Quality Management
关键词 疾病诊断相关组(DRGs) 绩效考核 医疗质量管理 Diagnosis Related Groups(DRGs) Performance Assessment Medical Quality Management
  • 相关文献

参考文献9

二级参考文献80

  • 1朱滨海.研究和实施DRGs时应考虑的若干问题[J].中华医院管理杂志,2006,22(7):456-459. 被引量:55
  • 2龚时薇,张敏,邓秀玲,何惠君,李燕,王祎.对我国罕见病与罕用药界定的思考[J].中国新药杂志,2006,15(15):1225-1229. 被引量:20
  • 3Alison Abbott. Rare - disease project has global ambi?tions[J] . Nature, 2011, (472): 17.
  • 4Wills Hughes - Wilson, Ana Palma, Ad Schuurman and Steven Simoens, Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Eu?rope to take account of new rare disease treatments?[J]. Or?phanetJournal of Rare Diseases, 2012 ( 7) : 74.
  • 5李定国专访.中国医学论坛报,2013年3月28日A9版.
  • 6刘轶琳,陈晓琪,曹子琛.委员连续4年为罕见病交提案不放弃救千分之一[EB].检索自http://gongyi.qq.eorrt/a/20120309/000001.htm,2012年3月8日发表/2013年9月30日检索引用.
  • 7左佰常,浙江政协委员提案呼吁:建立"罕见病"防治保障制度[EB].检索自http://health.zj01.conl.en/05zjhealth/system/2013/02/27/019175117.shtml,2013年2月28日发/2013年9月30日检索引用.
  • 8Wills Hughes - Wilson, Ana Palma, Ad Schuurman and Steven Simoens, Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Eu?rope to take account of new rare disease treatments?[J]. Or?phanetJournal of Rare Diseases, 2012(7) :74.
  • 9Chandana Thorat, Kui Xu, Scott N. Freeman, Renan A. Bonnel, FrancescaJoseph, M. Ian Philips and Menfo A. Imoisili, What the Orphan Drug Act has done lately for chil?dren with rare diseases: a 10 - year Analysis[J] . Pediatrics, 2012,129 (3): 516 -521.
  • 10Albert Van der Zeijden & Iolanda Huizer, Recommenda?tions for the development of national plans for rare diseases[J]. OrphanetJournal of Rare Diseases 2010, 5 (Suppl 1): 03.

共引文献149

同被引文献180

引证文献13

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部